Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
about
Follicular lymphoma: 2014 update on diagnosis and managementSystemic Front Line Therapy of Follicular Lymphoma: When, to Whom and HowImmune response to combination therapy for non-Hodgkin lymphomasWhen to treat patients with relapsed follicular lymphoma.Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma.Infections and Follicular Lymphoma: is there a Link?Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region.BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphomaElevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.Progression and Transformation of Clonally Heterogeneous B-cell Lymphoma.Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular EpidemiOutcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.Cell of origin of transformed follicular lymphomaLarge B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institutionEarly Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era.How we treat Richter syndrome.Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.XV. Clinical aspects of transformed lymphoma.Transformed follicular lymphoma (tFL): consolidation therapy may improve survival.Recommendations for Clinical Trial Development in Follicular Lymphoma.Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.Follicular lymphomas and their transformation: Past and current research.Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.Follicular lymphoma: 2015 update on diagnosis and management.Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.Life expectancy of young adults with follicular lymphoma.Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.
P2860
Q27021850-21932D2D-3CCB-4D74-B6C7-EB627A4C819AQ28073262-F3E6D109-25AE-471F-9BA4-594B2D596B8DQ28536423-050EDE49-6509-4EF4-A660-31AC5DB998EDQ30238528-998E629F-3061-4ECA-8F3D-4ABAB390EC0EQ30248407-19CEB93F-B2C4-4BA1-9E3A-BE8BEAA73321Q33628746-7670C22B-463A-475C-904D-1E0BA31C2CAFQ33642185-F69A31E9-4E69-45B5-A582-628B7C6FB789Q33670880-4FBA4095-A453-4062-82F7-2C9D6F042562Q33759661-B1728697-0831-4644-905E-4AB8165CD571Q33851726-BE20A4A8-C38E-4CF7-869E-0235EA369209Q34137923-742E01C8-3A3A-4C19-85A6-5A95F6038E97Q34288685-CFABF082-F90E-430B-AAAF-8F810574F5FBQ35004965-70DC8F68-ED67-44E1-A135-1B6670D04572Q35056309-91F13C74-6586-4267-85B6-24F1E8031D53Q35662002-15892006-F44A-47A4-918C-51CC7210A036Q35931755-71805F93-643F-4A19-AE6D-AC15730B68E3Q35979057-488CCD11-45C7-4CD4-83E3-4DFEA2CBDC38Q36222155-7B1D60A4-FEC5-460F-B480-441FF83E261CQ36225164-8B169138-0B3D-45AF-B39A-EAD75B08EBD8Q36825799-DC7F943D-1204-4670-9BAD-A2E5115E9F0FQ36934350-5CCFC80A-475A-44A7-AFDC-0424F77C8330Q37135341-EF897A7A-519F-469F-BBD0-AFEC4C2BD457Q37389643-60B9B267-3E2E-4473-821B-47CBBFE42906Q37636962-E40ED63A-E1ED-490C-8297-D6D1CF61CE4AQ38398064-4BE52CF8-9480-4447-9A83-D48046821878Q38416175-3AA98118-D0FB-4613-84FB-36F23E4516E1Q38524020-CA18AEBE-B782-4B5F-9FFF-BAC3602AEE18Q38891949-B626ED13-576B-4677-B86D-5D0507E581AFQ39063872-9C15B214-A4CC-4AA3-AE28-C3B893241411Q39221094-24E547C3-D798-4D3C-9E43-9D27D941104FQ39290214-D25B0F49-83E9-4444-804E-2FFDC9D04373Q39739502-10030FD3-4D7A-4463-BA03-1D8466123535Q39940415-50867F87-DAF2-4902-81D4-1AD961295E16Q40063998-A0C7D3BF-7392-42DB-807F-4A2788983AFEQ40122693-AD1BDA60-5DE3-4F17-8ED6-FFA6ED7DEA77Q40533698-BEB17B57-0D9B-435F-A756-89B0DE8804C8Q40683450-928FE0CA-3D35-40BB-94DB-E5CA974C7CE7Q41370330-26D103A7-7311-4F01-9A8B-CE0AD02423BCQ41489053-3CBC59E9-05F7-40AE-AB67-169D0572831FQ42388537-56963DB7-9141-4D31-B676-235E9E1754F9
P2860
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rates and outcomes of follicul ...... lecular Epidemiology Resource.
@en
Rates and outcomes of follicul ...... lecular Epidemiology Resource.
@nl
type
label
Rates and outcomes of follicul ...... lecular Epidemiology Resource.
@en
Rates and outcomes of follicul ...... lecular Epidemiology Resource.
@nl
prefLabel
Rates and outcomes of follicul ...... lecular Epidemiology Resource.
@en
Rates and outcomes of follicul ...... lecular Epidemiology Resource.
@nl
P2093
P2860
P356
P1476
Rates and outcomes of follicul ...... lecular Epidemiology Resource.
@en
P2093
Brian K Link
Carrie A Thompson
David J Inwards
Grzegorz S Nowakowski
James R Cerhan
Joseph P Colgan
Matthew J Maurer
Patrick B Johnston
Sergei I Syrbu
Stephen M Ansell
P2860
P304
P356
10.1200/JCO.2012.48.3990
P407
P577
2013-07-29T00:00:00Z